Photoacoustic imaging and artificial intelligence-based theranostic approach for cancer

健康计划渴望诊断成像和根除小于1 mm的耐药肿瘤病变。PHIRE，基于EDIT的结果（FET-OPEN-RIA，GA#801126），旨在将一种新型高分辨率治疗诊断医疗设备推向市场，该设备适用于小于1 mm病变的临床应用，可用于人类膀胱癌，对男性和女性患者均有效。PHIRE解决方案将使用猪模型开发，包括：- 用于预先存在的现成光声设备的附加模块，其允许执行位于人体中更深处的中空器官的光声成像，被设计为与以下结合使用：-用于图像引导的金纳米棒辅助光热疗法的人工智能辅助预测图，- 大规模合成尿液稳定的金纳米棒用于临床。采用这种新设备用于临床应用将减少膀胱肿瘤复发的频率和复发肿瘤患者的数量，对患者的生活质量产生巨大的积极影响，同时降低患者管理的社会成本。此外，PHIRE的成果将为其他中空人体器官中小于1 mm病变的治疗诊断应用开辟道路。PHIRE创新解决方案也将适用于其他市场，如光声和诊断成像、金纳米颗粒、膀胱镜检查和医疗软件。

Health programs crave for diagnostic imaging and eradication of chemoresistant neoplastic lesions smaller than 1 mm of size. PHIRE, based on the outcomes from EDIT (FET-OPEN-RIA, GA#801126), aims at bringing closer to market a novel high-resolution theranostic medical device effective in the clinical applications for lesions <1 mm, ready for application in human bladder cancer and effective both in male and female patients.The PHIRE solution will be developed using swine model and will include:- an add-on module for pre-existing off-the shelf photoacoustic device allowing to perform photoacoustic imaging of hollow organs located deeper in human body, designed to be used in combination with- an artificial intelligence-assisted prediction map for the image-guided gold nanorods assisted photo-thermal therapy,- a large-scale synthesis of urine-stable gold nanorods for clinical use.The adoption for clinical applications of this new device will reduce the frequency of the bladder tumor relapse and the number of patients with relapsing tumor, with a drastic positive impact on the quality of life of patients while reducing the social cost of the management of patients. Furthermore, PHIRE’s results will open up the way for the deployment of theranostic application against lesions <1 mm in other hollow human organs.PHIRE innovative solutions will also be applicable to other markets, such as that of photoacoustic and diagnostic imaging, gold nanoparticles, cystoscopy and medical software.